Myriad Genetics, Inc. (NASDAQ: MYGN) strengthens its commitment to the future of precision medicine with the appointment of renowned oncologist Adam Brufsky, MD, PhD, FACP as Scientific Advisor to its oncology business unit. In this capacity, Dr. Brufsky will provide his expertise to inform and propel Myriad’s unique Precise™ Oncology Solutions that promise to revolutionize cancer care approaches for patients everywhere.
Myriad Genetics is proud to welcome Dr. Adam Elsesser as the new Head of Oncology. His exceptional academic and research expertise, combined with a wealth of clinical experience, makes him an ideal choice to spearhead our vision for growth and evolution in the oncology space. Michael Lyons, General Manager of Oncology, praised Dr. Elsesser’s extraordinary qualifications and commitment to the field. We are certain that his addition to our team will make a lasting impression.
Dr. Brufsky is an incredibly accomplished Professor of Medicine at the University of Pittsburgh School of Medicine. With board certifications in both internal medicine and medical oncology, he earned his medical and Doctor of Philosophy degrees from the University of Connecticut School of Medicine, followed by a residency at Brigham and Women’s Hospital, Harvard Medical School and a fellowship in medical oncology at Dana-Farber Cancer Institute. His expertise and knowledge is unprecedented, making him a leading expert in the field.
About Myriad Genetics
Myriad Genetics is devoted to enriching the health and wellbeing of all humanity through the use of precision medicine and cutting-edge genetic testing. Our tests can be used to ascertain the risk of developing or worsening medical conditions, opening the doors to smarter therapeutic decisions for healthcare professionals. By uncovering the most meaningful genetic insights, Myriad strives to improve patient care and minimize healthcare costs.
Safe Harbor Statement
The future of oncology could be transformed with the important contributions of Dr. Brufsky, as announced by Myriad. Through his leadership role at the company, he will drive growth and deliver groundbreaking innovations, according to the company’s long-term vision. However, there are risks to consider before fully embracing this new direction.
Myriad’s filings to the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K filed on March 1, 2021, list out the various risk factors that can affect this path. Although Myriad is not obligated to update or change any of their forward-looking statements, they don’t rule out doing so in the future should the need arise.